EPISODE · Nov 8, 2025 · 9 MIN
Aulos Bioscience presented phase 2 data at SITC for its antibody that binds to IL-2 and prevents CD25 binding - showing responses in melanoma and lung
from BiotechTV - News · host BiotechTV
CEO Aron Knickerbocker walks us through the data and describes why he believes imneskibart's ability to show a higher Teff/Treg ratio in patients, and how it correlates with longer time on treatment and overall survival, may be unique in the IL-2 class.
Embed this episode
NOW PLAYING
Aulos Bioscience presented phase 2 data at SITC for its antibody that binds to IL-2 and prevents CD25 binding - showing responses in melanoma and lung
0:00
9:41
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 9 minutes long.
When was this BiotechTV - News episode published?
This episode was published on November 8, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!